Reintroducing
Reintroducing
About us / Press room
News about our community
Our actions match our words
December 6, 2017
Scholarships Awarded to Students with Dermatologic Conditions

Scholarships were awarded to 9 recipients through the Aspire Higher Scholarship program. The winners of the program are applicants or current attendees of an accredited, nonprofit, 2- or 4-year college, university, or advanced (post-high school) vocational or technical school who have been treated for a dermatologic condition.

November 14, 2017
ORTHO DERMATOLOGICS ANNOUNCES ASPIRE HIGHER SCHOLARSHIP HONOREES

Scholarship Program Awards Students Across the Country Impacted by Dermatologic Conditions 

Raleigh, NC, November 14, 2017 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, today announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or four-year college, university, or advanced (post-high school) vocational or technical school who have been treated for a dermatologic condition.

November 2, 2017
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR IDP-118, NOVEL PLAQUE PSORIASIS TREATMENT

PDUFA Date Set for June 18, 2018

LAVAL, Quebec, Nov. 2, 2017 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018.

If approved, IDP-118 will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.

The most common adverse events were contact dermatitis (7.4%) and application site pain (2.6%).

October 12, 2017
ORTHO DERMATOLOGICS ANNOUNCES TWO-YEAR FINDINGS FROM PIVOTAL PHASE 3 STUDY OF SILIQ™ (BRODALUMAB) INJECTION DATA DEMONSTRATING LONG-TERM EFFICACY PROFILE

Data Sets Demonstrating Efficacy and Quality of Life Profile of SILIQ Presented at 2017 Fall Clinical Dermatology Conference

RALEIGH, N.C., Oct. 12, 2017 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced results from the Pivotal Phase 3 long-term extension study (AMAGINE-2), which demonstrated that SILIQ™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis. These findings are being presented for the first time today at the 2017 Fall Clinical Dermatology Conference in Las Vegas.

October 10, 2017
ORTHO DERMATOLOGICS TO PRESENT SILIQ™ (BRODALUMAB) INJECTION DATA FROM PIVOTOL PHASE III CLINICAL TRIAL AT FALL CLINICAL DERMATOLOGY CONFERENCE

RALEIGH, N.C., Oct. 10, 2017 – Ortho Dermatologics, one of the largest prescription dermatology businesses in the world, announced today that results from the SILIQ™ pivotal Phase 3 long-term extension study will be presented at the Fall Clinical Dermatology Conference in Las Vegas on October 12 – 15, 2017. In total, six new abstracts will be presented, including new data about the long-term efficacy of SILIQ, the efficacy of SILIQ in ustekinumab-naïve and -experienced patients with moderate-to-severe plaque psoriasis, as well as the impact of SILIQ treatment on health-related quality of life.

September 5, 2017
Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118

Novel Investigational Topical Lotion with Unique Formulation Targets the Treatment of Plaque Psoriasis

LAVAL, QuebecSept. 5, 2017 /PRNewswire/ — Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced it has submitted a New Drug Application (NDA) to the  U.S. Food and Drug Administration  ( FDA ) for IDP-118 (halobetasol propionate and tazarotene) lotion . IDP-118 is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of plaque psoriasis.

July 27, 2017
Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection

LAVAL, Quebec, July 27, 2017 – Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the launch of SILIQ™ (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York from July 27-30, 2017. SILIQ, a monoclonal antibody that targets the IL-17 receptor A, is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

May 8, 2017
Valeant Dermatology Announces New Senior Leadership Team

BRIDGEWATER, NJ – May 8, 2017 – Valeant Dermatology, one of the largest prescription dermatology companies in the United States, today announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The senior team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn, vice president of professional and specialty development; Ed Shupenus, executive director of marketing operations; and Steve Kreider, executive director of sales and marketing for SILIQ™ (brodalumab) injection, for subcutaneous use.

X
X
X